Brief: Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat
27/03/2024 20:08
March 27 (Reuters) - Sagimet Biosciences Inc SGMT.O :
* SAGIMET BIOSCIENCES ANNOUNCES COMPLETION OF PHASE 1
HEPATIC
IMPAIRMENT STUDY WITH FASN INHIBITOR DENIFANSTAT
Source text for Eikon: ID:nGNX9H5NcX
Further company coverage: SGMT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sagimet Biosciences
See all newsBrief: Sagimet Biosciences Announces Pricing Of $115.0 Million Underwritten Offering Of Series A Common Stock And Pre-Funded Warrants
Brief: Sagimet Biosciences - Suspends And Terminates ATM Prospectus Supplement For Series A Common Stock Effective Sept 30
Brief: Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial Of Denifanstat In Acne Toward Patient Enrollment In Q4 2026
Brief: Sagimet Biosciences Phase 3 Clinical Trial Is On Track To Initiate In Second Half Of 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage